{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T23:37:37Z","timestamp":1792193857270,"version":"4.4.0"},"reference-count":31,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw -The Netherlands Organisation for Health Research and Development","doi-asserted-by":"crossref","award":["10140022110029"],"award-info":[{"award-number":["10140022110029"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,17]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Cardiovascular events (CVEs), in particular acute coronary syndrome (ACS), complicate the course of a significant number of patients hospitalised for community-acquired pneumonia (CAP) or influenza. Emerging evidence suggests that this increased risk of CVEs could be mitigated by the use of acetylsalicylic acid (aspirin). The ASCAP study investigates whether the addition of aspirin to standard therapy in hospitalised patients with moderate-to-severe CAP or influenza can reduce the incidence of CVEs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The ASCAP study is a multicentre, double-blind, placebo-controlled randomised trial in 16 university and general hospitals in the Netherlands, in which patients are randomised to acetylsalicylic acid or matching placebo for 90 days. Eligible patients are adults hospitalised for moderate-to-severe CAP or influenza. Patients with antithrombotic or anticoagulant drugs, or those with contraindications for aspirin, are excluded. The primary outcome is the incidence of ACS up to day 180. Secondary outcomes include the incidence of 4-point major adverse cardiovascular events up to day 180, as well as the incidence of major bleeding and clinically relevant non-major bleeding events up to day 90, all-cause mortality up to day 180 and quality of life and societal costs up to day 180. Survival time will be analysed by the log-rank test, stratified for CAP and influenza, with a two-sided alpha of 0.05. Assuming an average baseline ACS risk of 7.5% over 180 days with up to 30% variation across strata, and a 60% hazard reduction due to aspirin, the required sample size to achieve 80% power is 760 patients. Currently, 114 patients are enrolled in the study.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Ethics and dissemination<\/jats:title>\n                    <jats:p>This study is approved by the Medical Ethics Committee Amsterdam UMC (Amsterdam, The Netherlands) under reference number 2023.0741 and registered under EU trial number 2023-504553-12-01 in the EU portal CTIS (Clinical Trials Information System). Results of the study will be published in a peer-reviewed journal.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Trial registration number<\/jats:title>\n                    <jats:p>EU CTIS: 2023-504553-12-01.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-110210","type":"journal-article","created":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T06:20:28Z","timestamp":1762410028000},"page":"e110210","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Aspirin to prevent cardiovascular events in patients with community-acquired pneumonia or influenza (ASCAP study): protocol for a multicentre, randomised, double-blind, placebo-controlled trial"],"prefix":"10.1136","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-2317-6645","authenticated-orcid":false,"given":"Vahram","family":"Hovsepjan","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Institute for Immunology and Infectious Diseases, The Amsterdam, Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abel","family":"Thijs","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeske J K","family":"van Diemen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3389-5141","authenticated-orcid":false,"given":"Johannes A","family":"Bogaards","sequence":"additional","affiliation":[{"name":"Department of Epidemiology and Data Science, Amsterdam UMC, Amsterdam, The Netherlands"},{"name":"Amsterdam Public Health Research Institute, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michiel M","family":"Winter","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Amsterdam UMC - Locatie AMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith E","family":"Bosmans","sequence":"additional","affiliation":[{"name":"Amsterdam Public Health Research Institute, Amsterdam, The Netherlands"},{"name":"Department of Health Sciences, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan M","family":"Prins","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Amsterdam UMC, Amsterdam, The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2025,11,5]]},"reference":[{"key":"2025120413261430000_15.11.e110210.1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix164"},{"key":"2025120413261430000_15.11.e110210.2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.122.061183"},{"key":"2025120413261430000_15.11.e110210.3","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300361","article-title":"Influenza Infection and Acute Myocardial Infarction","volume":"3","author":"de Boer","year":"2024","journal-title":"NEJM Evid"},{"key":"2025120413261430000_15.11.e110210.4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001048","article-title":"Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies","volume":"8","author":"Corrales-Medina","year":"2011","journal-title":"PLoS Med"},{"key":"2025120413261430000_15.11.e110210.5","doi-asserted-by":"publisher","DOI":"10.1086\/589246"},{"key":"2025120413261430000_15.11.e110210.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa041747"},{"key":"2025120413261430000_15.11.e110210.7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra1808137"},{"key":"2025120413261430000_15.11.e110210.8","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577303","article-title":"Platelets and Their Role in the Pathogenesis of Cardiovascular Events in Patients With Community-Acquired Pneumonia","volume":"11","author":"Feldman","year":"2020","journal-title":"Front Immunol"},{"key":"2025120413261430000_15.11.e110210.9","doi-asserted-by":"crossref","first-page":"3501","DOI":"10.1007\/s10238-023-01101-5","article-title":"The efficacy of aspirin to inhibit platelet aggregation in patients hospitalised with a severe infection: a multicentre, open-label, randomised controlled trial","volume":"23","author":"van Zijverden","year":"2023","journal-title":"Clin Exp Med"},{"key":"2025120413261430000_15.11.e110210.10","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.324.7336.S71"},{"key":"2025120413261430000_15.11.e110210.11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.114.001595","article-title":"Lower mortality rate in elderly patients with community-onset pneumonia on treatment with aspirin","volume":"4","author":"Falcone","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"2025120413261430000_15.11.e110210.12","doi-asserted-by":"crossref","first-page":"02795","DOI":"10.1183\/13993003.02795-2020","article-title":"Aspirin reduces cardiovascular events in patients with pneumonia: a prior event rate ratio analysis in a large primary care database","volume":"57","author":"Hamilton","year":"2021","journal-title":"Eur Respir J"},{"key":"2025120413261430000_15.11.e110210.13","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2008.06.030"},{"key":"2025120413261430000_15.11.e110210.14","doi-asserted-by":"publisher","DOI":"10.1097\/MCA.0b013e32835d7610"},{"key":"2025120413261430000_15.11.e110210.15","doi-asserted-by":"publisher","DOI":"10.1136\/thorax.58.5.377"},{"key":"2025120413261430000_15.11.e110210.16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199701233360402"},{"key":"2025120413261430000_15.11.e110210.17","unstructured":"Farmacotherapeutisch Kompas . Maagbescherming. 2021 Available: https:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/indicatieteksten\/maagbescherming"},{"key":"2025120413261430000_15.11.e110210.18","unstructured":"De Jongh E , De Wit NJ , Numans ME , et al . Preventie van maagcomplicaties door geneesmiddelgebruik. NHG; 2025. Available: https:\/\/richtlijnen.nhg.org\/behandelrichtlijnen\/preventie-van-maagcomplicaties-door-geneesmiddelgebruik#volledige-tekst"},{"key":"2025120413261430000_15.11.e110210.19","unstructured":"Daalen FV , Boersma WG , van de Garde EMW , et al . Management of community-acquired pneumonia in adults: the 2024 practice guideline from the Dutch working party on antibiotic policy (SWAB) and dutch association of chest physicians (NVALT). SWAB Guidelines; 2024."},{"key":"2025120413261430000_15.11.e110210.20","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"2025120413261430000_15.11.e110210.21","doi-asserted-by":"publisher","DOI":"10.1111\/jth.13140"},{"key":"2025120413261430000_15.11.e110210.22","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01204.x"},{"key":"2025120413261430000_15.11.e110210.23","unstructured":"iMTA . Manual imta medical cost questionnaire (IMCQ). Rotterdam iMTA, Erasmus University Rotterdam; 2018."},{"key":"2025120413261430000_15.11.e110210.24","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jval.2015.05.009","article-title":"The iMTA Productivity Cost Questionnaire: A Standardized Instrument for Measuring and Valuing Health-Related Productivity Losses","volume":"18","author":"Bouwmans","year":"2015","journal-title":"Value Health"},{"key":"2025120413261430000_15.11.e110210.25","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"2025120413261430000_15.11.e110210.26","doi-asserted-by":"publisher","DOI":"10.2307\/2531021"},{"key":"2025120413261430000_15.11.e110210.27","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/0021-9681(85)90123-7","article-title":"Consideration of covariates and stratification in sample size determination for survival time studies","volume":"38","author":"Palta","year":"1985","journal-title":"J Chronic Dis"},{"key":"2025120413261430000_15.11.e110210.28","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<681::AID-SIM71>3.0.CO;2-R","article-title":"Multiple imputation of missing blood pressure covariates in survival analysis","volume":"18","author":"van Buuren","year":"1999","journal-title":"Statist Med"},{"key":"2025120413261430000_15.11.e110210.29","doi-asserted-by":"publisher","DOI":"10.2307\/2670170"},{"key":"2025120413261430000_15.11.e110210.30","unstructured":"Nederland Z . Richtlijn voor het uitvoeren van economische evaluaties in de gezondheidszorg. Diemen; 2024."},{"key":"2025120413261430000_15.11.e110210.31","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0160046","article-title":"Bleeding Risk with Long-Term Low-Dose Aspirin: A Systematic Review of Observational Studies","volume":"11","author":"Garc\u00eda Rodr\u00edguez","year":"2016","journal-title":"PLoS One"}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-110210","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:27:21Z","timestamp":1764883641000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-110210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":31,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,5]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-110210"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-110210","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"value":"2044-6055","type":"print"},{"value":"2044-6055","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}